BioSpace News Archive

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, announces that the first patient has received the first dose in an international Phase I/II clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA® (pembrolizumab) for patients with non-small cell lung cancer (NSCLC) – NCT03562871.

This week marks the official start of “flu season” for 2018-2019. The FDA, along with its partners across the Department of Health and Human Services, has been working throughout the year to prepare the development of a safe, effective flu vaccine for the season.

The board of directors of Pfizer Inc.. today declared a 34-cent fourth-quarter 2018 dividend on the company’s common stock, payable December 3, 2018, to shareholders of record at the close of business on November 9, 2018.

Nonprofit addiction treatment leader says bill advances several key priorities in effort to confront nation’s most urgent public health issue

Ultragenyx Pharmaceutical Inc.(NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced topline positive safety and efficacy data from the second dose cohort and positive longer-term data from the first dose cohort of the ongoing Phase 1/2 study of DTX301.

Despite the current opioid epidemic that has riveted public attention on addiction, as little as 10 percent of the nearly 20 million people in the United States struggling with drugs and alcohol receive treatment

AMN Healthcare has again been recognized by The Joint Commission for its commitment to placement of high-quality clinicians throughout the healthcare industry.

Teva Pharmaceutical Industries Ltd. today announced the exclusive first-to-file launch of a generic version of Cialis®1 (tadalafil) tablets (2.5 mg, 5 mg, 10 mg, 20 mg) in the U.S.

Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.

Regulus Therapeutics Inc. today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company overview at the Cantor Fitzgerald Global Healthcare Conference in New York City on Monday, October 1, 2018.